TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Exercise load end blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise load end perceived effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 7-day child consumption of sugar-sweetened beverages and 100% fruit juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery 40 scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional connectivity between R MFG and brain regions within VAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: patient satisfaction for masticatory ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mental life comfortability with dentures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in score on Child Planned Activities Training (cPAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in scores on Parenting Young Children (PARYC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in score on How to Keep your Child Safe and Healthy Quiz
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in score on Brief Child Abuse Potential Inventory (BCAPI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to Maximal Blood Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Groin recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of foot abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microcirculation of blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Upper Limb Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of coronary microvascular dysfunction and/or coronary artery vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local Skin Reactions (LSRs)
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-12 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative change of cerebrospinal-plasma albumin ratio (CPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity alopecia tool score - SALT score I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alopecia Areata Progression Index, AAPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Ropivacaine Plus Magnesium Sulphate Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year mortality after valvular heart surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale Cognitive Subscale 12 [ADAS Cog12]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of restrictions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of aggression events
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of KUC-7483
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of life at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Radiation Therapy (RT) Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Radiation Therapy (RT) Adherence Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Therapy (RT) Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Skin Carotenoid Status at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Carotenoid Status at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC from time zero to the last data point (AUC-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of adverse events and adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Clinicians' perception of seizure probability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Clinicians' decisions to recommend commencing or deferring anti-seizure medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change From Baseline in Microtopographic Profilometry Ra Values (Skin Roughness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change From Baseline in Microtopographic Profilometry Rz Values (Rhytid Depth and Severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Belief in exercise or physical activity program effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Integrated fractional synthesis rate (%/d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumour uptake of 68Ga-NTA-476
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ß-CTX (Bone Resorption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in P1NP (Bone Formation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive and Insight Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Volume of the ischemic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-traumatic stress syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consistency of LGE-MRI fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EAM low-voltage area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Urine PolypDx device in detecting colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative Blood Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fugl Meyer Assessment Scale - Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 68Ga-FAPI-46 compared to 18F-FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of Intra-nasal Sufentanil for Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCG recovery from intradermal challenge site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of days without mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in apixaban concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease rate of irAEs ≥ grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Negative RT-PCR for plasmodium reservoirs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Persistence of Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fine motor skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pensacola Diagnostic Index-based motion sickness questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COG Sway velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in weekly anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS pain impact score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: TMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2D Echo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Time in Range Glucose Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment success evaluated by VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding on probing change % reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete renal response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proteinuria measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of postural stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with detectable T-cell response to CMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with detectable T-cell response to ADV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with detectable T-cell response to EBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with Modified Rankin Scale (mRS) Score 0-1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antibody titre for Immunoglobulin (IgG) anti-SARS-CoV-2 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RR values for exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of ACH provoked spasm no longer inducible
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rebound hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gait kinematic of pelvic hip, knee and ankle joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vastus lateralis muscle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Uptake of HIV Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Peak torque of Isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in cardiovascular risk profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of dose limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Inactivation of root caries lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual plasma level of emicizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F VASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HRPP with high risk polypharmacy measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide ideation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects with radiological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of Medication for Opioid Use Disorder (MOUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized uptake value (SUV) of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F-FDG uptake rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety evaluation of IMD
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in DCP_001 vaccine antigen-specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Dose-limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Effective rate on proteinuria treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean reduction in wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of A-responses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of hospital stay (LOS) in hours following delivery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient-reported ready for discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of points detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between perceived and actual stimulus location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-vision visual functioning questionnaire (LV-VFQ-48)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Humphrey visual field test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of trabecular at distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skeletal outcomes
Primary endpoint: number of trabecular at distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skeletal outcomes
Primary endpoint: Target lesion failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Post-Anesthetic Discharge Scoring System (PADSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in standardized tapping with a device for PIVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with complete intake of PEG solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with change in GI side effects related to PEG solution
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: all-cause mortality at six months post-surgery
Endpoint domain: Mortality/survival
Primary endpoint: all-cause mortality at twelve months post-surgery
Endpoint domain: Mortality/survival
Primary endpoint: recurrent blood culture positive infection
Endpoint domain: Adverse events/effects
Primary endpoint: cardiac re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Percent Days Abstinent (PDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol cue task MRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excessive bleeding blood loss ≥ 300 mills after PPH treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-reported pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotational deviation (Axial plane deviation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Fusarium sp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the excitability/strength of the brain-spinal cord-muscle pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in ability to move the arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of ITGA2b and SELP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain immediately after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain before leaving the office
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV Treatment Initiation Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy rate of jawline contour deficit improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentration in plasma at 24 hours post-dose (C24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in fatty liver index (FLI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hepatic steatosis index (HSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical Success of EUS-FNA plus MFB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success of EUS-FNA plus MFB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of EUS-FNA plus MFB
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Dehydrogenase (LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean mass and fat mass post-supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone mineral density post-supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight post-supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Photos Identified Correctly at 30 Day Follow Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Photos Identified Correctly at 90 Day Follow Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Intuitive Eating Behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotional wellness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unplanned extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Isokinetic Upper Extremity Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Core Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cancer survivors with modifiable health risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clearance at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical mucus by modified Insler score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Oral Disposition Index (oDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Protein Density Fat Fraction (PDFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful placement of a venous catheter on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of workplace violence
Endpoint domain: Adverse events/effects
Primary endpoint: Impact on the individual employee/worker
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mortality or severe intracranial hemorrhage (ICH) before discharge
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean fold rise (GMFR) of neutralization antibody titre in the high dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes